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Patients with epilepsy have a threefold risk of completed
suicide,1 and a twofold risk of suicidal ideation2 compared to
normal controls. The causes are not well understood, although
some risk factors such as pre-existing psychiatric disorders and
epilepsy surgery have been identiﬁed.3
A metaanalysis conducted by the US Food and Drug Adminis-
tration (FDA) based on 199 placebo-controlled antiepileptic drug
(AED) trials with approximately 28,000 patients in the active arms,
and approximately 16,000 patients in the placebo arms reported an
increased risk for suicidality in the actively treated patients (odds
ratio 1.8).4 However, this meta-analysis did not distinguish
between different substances or AED classes. In addition, a
metaanlysis using studies with the same AED substances in
patients with bipolar disorders could not ﬁnd increased suicide
risk in AED use compared with use of Lithium or non-AED
substances.5 All comparable analyses are hampered by a relatively
low event rate resulting in wide conﬁdence intervals. Thus, the
contribution of individual AED substances to the risk of suicide or
suicidal ideation remains unclear.
Lacosamide is a relatively new AED that is thought to exert its
anticonvulsant effect by modulation of voltage-dependent sodium
channels.6 During the large mandatory placebo-controlled studies
needed for licensation, depression or suicidal ideation was rare and
no difference was found between the active arms and the placebo
arms of the studies. In contrast to some other AED such as* Correspondence address: Department of Neurology, Klinikum Osnabru¨ck, Am
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pre- and post-marketing data suggested increased risk of depres-
sion,7,8 no such signal exists for lacosamide.
We report a patient with refractory partial epilepsy who
experienced reversible phase of mood instability and suicidal
ideation after exchanging levetiracetam by lacosamide.
2. Case report
We report the case of a 47-year-old man suffering from partial
epilepsy since 31 years. His seizures start with visual sensations
followed by loss of responsiveness and oro-alimentary automa-
tisms and ﬁnally clonic movements of the left face and arm. His
seizures had been refractory to phenytoin, valproate, lamotrigine,
carbamazepine, levetiracetam, and oxacarbazepine. In October
2011, he underwent long-term video-EEG-monitoring. His typical
seizures could be documented associated with right-hemispheric
EEG seizure patterns, but additionally there were subclinical
seizures arising from the left temporo-parietal region. Interictal
EEG showed frequent intermittent slowing in the right temporal
region, and spikes arising predominantly from the right anterior
temporal region, more rarely from the left temporal region. MRI
demonstrated bilateral nodular heterotopias bordering to both
lateral ventricles. Therefore, he was not thought to be a candidate
for epilepsy surgery. During the video-EEG monitoring, levetir-
acetam had been tapered off and oxcarbazepine was reduced to
increase the chance of seizure occurrence. Immediately after
ﬁnishing the video-EEG-monitoring, oxcarbazepine was increased
to its old daily dose of 1500 mg, and levetiracetam was substituted
by lacosamide. During the remaining few days of in-patient
treatment, lacosamide was increased to its target dose of 400 mg
per day (200 mg b.i.d.). During the rapid titration, the patient
experienced mild tiredness that ceased after 2 days. He underwent
neuropsychological testing that demonstrated decreased memo-
ry abilities for verbal material and deﬁcits in verbal ﬂuency, but
average to high average abilities in most other categories. At that
point, Beck’s depression inventory (BDI) was performed and
showed no evidence for depressive tendencies (7 points in BDI).
He had never undergone psychotherapy, other psychiatric
therapy, or counselling, in his life. He was discharged without
complaints on October 18th. Two weeks after discharge, he
presented in the epilepsy outpatient clinic and stated that he had
not experienced any seizures nor any unwanted side effects of the
medication. Serum levels of oxcarbazepine and lacosamide were
17.8 mg/l (10-OH-metabolite) and 5.6 mg/l, respectively. Onvier Ltd. All rights reserved.
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reported two seizures since the last visit, and complained of mild
tiredness approximately 2 h after morning intake. His routine EEG
showed no changes to the interictal EEG documented during
presurgical video-EEG monitoring. He was told to split the
morning dose of both lacosamide and oxcarbazepine and take one
half in the morning, the other half at noon. At that visit, he seemed
to be balanced and at ease with himself. No psychiatric symptoms
were detected.
On December 31st, the patient presented at the emergency
department of the hospital. He told that in the past week, he
increasingly had experienced mood swings with predominantly
depressive thoughts that he had never experienced before. In
addition, he reported suicidal thoughts with death wishes that
were completely new to him and frightened him because they
seemed unnormal to him. During examination, his mood was
depressed, he was tense and lacked his usual drive. He was
admitted to the neurology ward because a drug side effect was
assumed. Lacosamide was stopped, and levetiracetam was
reinstituted at the formerly well-tolerated dose of 2000 mg/d
(dose at admission to video-EEG monitoring in October 2011:
4000 mg/d). After 3 days, he had recovered completely. He did not
show any mood abnormalities and stated that he felt like usual
again. He declined any suicidal thoughts. After thorough psychiat-
ric evaluation by an independent psychiatrist, he was discharged.
During the following two weeks, levetiracetam was tapered and
pregabalin was added, starting with 75 mg twice per day.
Afterwards, he was seen every 6–8 weeks in the outpatient clinic.
During the complete follow up until September 2012, i.e. 9 months
after the incident, he did not show any sign of depression again. At
each of his regular outpatient visits, he was asked about suicidal
thoughts, and always declined them. His mood was stable and he
seemed balanced in spite of his ongoing seizures that could not be
controlled with his current combination therapy consisting of
pregabalin (600 mg per day) and oxcarbazepine (1200 mg per day).
Repeated routine EEG did not show any differences to the
recordings before and during lacosamide intake.
3. Discussion
This patient experienced a sudden episode of depression and
suicidal ideation that was clearly associated with the new onset
therapy with lacosamide. Although no formal psychiatric evalua-
tion had been performed before initiation of lacosamide, stan-
dardized testing (BDI) showed no evidence for a comorbid mood
disorder, and there was no family history of suicidal ideation. In
addition, none of the established risk factors for suicidality in
patients with epilepsy such as newly diagnosed epilepsy or recent
epilepsy surgery3 was present. No mood-stabilizing agent had
been tapered off, and no negative pharmacokinetic effect reducing
the efﬁcacy of a potential mood stabilizing AED could account forthe symptoms. To the contrary, the drug preceding lacosamid was
levetiracetam, a substance that is associated with an increased risk
of depression.8 The complete reversibility of the symptoms after
cessation of lacosamide also speaks in favour of a causal
relationship between the suicidality and the substance.
Lacosamide was titrated in a rapid fashion. This could have
contributed to the occurrence of the symptoms. However, there
was a time lag of more than 6 weeks between titration and
symptom onset. Therefore, it seems unlikely that the speed of
titration was a signiﬁcant risk factor. Unfortunately, serum levels
for lacosamide during the suicidal episode are not available.
Therefore, accidental overdosing or decrease of clearance cannot
be ruled out completely.
This is a single case report, thus one cannot draw conclusions as
to a systematic effect of lacosamide on mood and depression. Since
approval of the drug, there have been unpublished cases of
depression and/or suicidal behaviour that have been included in
the current physician’s manual. In addition, behavioural problems
have been seen in children treated with lacosamide.9 However,
systematic data are still missing for this (as well as other)
substance(s). Standardized screening for suicidality should not
only performed in the pivotal phase III studies, but should also be
mandatory for post-marketing surveillance of anticonvulsants as
well as for other substances acting in the central nervous system.
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